SCHEMBL6926049

SCHEMBL6926049

O=Cc1ccc(COc2ccc(Cl)cc2)o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
KMT2A Q03164 5/20 0.48
MAPT P10636 4/20 0.48
TSHR P16473 3/20 0.47
ALDH1A1 P00352 3/20 0.47
MEN1 O00255 4/20 0.45
DAO P14920 1/20 0.44
NPC1 O15118 4/20 0.43
KDM4E B2RXH2 3/20 0.43
LMNA P02545 2/20 0.43
HPGD P15428 2/20 0.43
PRMT5 O14744 1/20 0.43
CASP1 P29466 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
POLB P06746 4/20 0.41
RAB9A P51151 3/20 0.40
EYA2 O00167 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7132970 0.84 SMN1; SMN2 (0.51) HSD17B10SMN1; SMN2KMT2AMAPTTSHR
SCHEMBL6829232 0.84 NPC1 (0.50) HSD17B10SMN1; SMN2KMT2AMAPTTSHR
SCHEMBL6923514 0.84 ALDH1A1 (0.47) SMN1; SMN2KMT2AMAPTTSHRALDH1A1
SCHEMBL6829615 0.83 ALDH1A1 (0.50) HSD17B10SMN1; SMN2KMT2AMAPTTSHR
SCHEMBL6441520 0.83 DAO (0.49) HSD17B10SMN1; SMN2KMT2AMAPTTSHR
SCHEMBL6829041 0.83 SMN1; SMN2 (0.41) HSD17B10SMN1; SMN2KMT2AMAPTTSHR
SCHEMBL6923684 0.80 ALDH1A1 (0.44) HSD17B10SMN1; SMN2MAPTTSHRALDH1A1
SCHEMBL6919445 0.80 MAOB (0.44) KMT2ATSHRALDH1A1MEN1NPC1
SCHEMBL7133523 0.80 NPC1 (0.60) SMN1; SMN2KMT2AMAPTTSHRALDH1A1
SCHEMBL6922355 0.78 CYP1A2 (0.46) HSD17B10SMN1; SMN2KMT2AMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4196108-A1 QUORUM SENSING INHIBITORS AND METHODS OF USE The Trustees of Indiana University (US) 2023-06-21 EP disclosed
WO-2022036282-A1 QUORUM SENSING INHIBITORS AND METHODS OF USE THE TRUSTEES OF INDIANA UNIVERSITY (US) 2022-02-17 WO disclosed
US-10875834-B2 Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-HMF) and its derivatives VIRGINIA COMMONWEALTH UNIVERSITY (US) 2020-12-29 US disclosed
WO-2004037808-A1 2 - SUBSTITUTED HETEROCYCLIC COMPOUNDS AND ANTITUMOR COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10875834-B2 Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-HMF) and its derivatives MTHFD1, MTHFD2, ADH5 HSD17B10 527/4885SMN1; SMN2 384/4885KMT2A 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.